Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

May 3, 2022

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 71 min

Earnings Call Speaker Segments

Jee Hamlyn-Harris

executive
#1

Thanks, operator, and I appreciate everyone being here today as we go over Penumbra's results for Q1 2022. You can find the press release along with the financial tables — including the reconciliation from GAAP to non-GAAP — on the Investors section of our site, www.penumbrainc.com. On this call, we'll be making forward-looking statements under the safe harbor protections of the Private Securities Litigation Reform Act of 1995, covering things like our financial performance, commercialization efforts, clinical trials, regulatory status, quality compliance, and business trends. Actual outcomes may differ materially from what those forward-looking statements state or suggest, because of certain risks and uncertainties, such as the ones described in our 10-K for the year ended December 31, 2021, filed with the SEC. So we urge you not to place undue reliance on these forward-looking statements, and we encourage you to look at our periodic filings with the SEC, including that 10-K, for a fuller discussion of these factors and other risks that could affect our future results or the market price of our stock, including, but not limited to, how the COVID-19 pandemic impacts our business, results of operations and financial conditions. Penumbra disclaims any duty to update or revise our forward-looking statements as a result of new information, future events, developments or otherwise; on this call, certain financial measures are presented on a non-GAAP basis. The corresponding GAAP measures and a reconciliation of GAAP to non-GAAP financial measures are provided in our posted press release. We expect the prepared remarks today to take about 25 minutes. Adam Elsesser, Penumbra's Chairman and CEO, will give a business update; Maggie Yuen, our Chief Financial Officer, will then go over our financial results for the first quarter; and Jason Mills, our Executive Vice President of Strategy, will cover our 2022 guidance. With that, I'll hand the call over to Adam Elsesser.

Adam Elsesser

executive
#2

Thanks, Jee. Hello, everyone. I appreciate you being on Penumbra's call for the first quarter of 2022. Revenue across the company came to $203.9 million in Q1, which represents 20.5% growth compared to the same period last year as reported, and 21.8% on a constant currency basis. Gross margin went up 100 basis points from the prior quarter, reaching 62.5%, and I believe the significant investments we've put into our team, our offerings, and our manufacturing during the last 2 years will keep driving both solid growth and further gross margin gains moving forward. Let me quickly cover how things went in the first quarter across our Vascular, Neuro, and Immersive Healthcare segments, and after that I'll share some broader thoughts on the business, outline our new product road map, and discuss the growth opportunities we foresee; within Vascular, we posted 37.7% year-over-year growth, hitting $122.8 million in Q1. Vascular thrombectomy revenue rose 43.2% from a year earlier, while vascular embolization revenue climbed 28.8% year-over-year. The increase in vascular thrombectomy came from ongoing strong uptake of our Lightning products in the United States. We achieved sequential growth in every part of our U.S. thrombectomy business: DVT, PE, arterial and coronary. Our U.S. vascular thrombectomy business delivered robust 30% year-over-year growth. We also moved into China alongside our partner Genesis; this broadened partnership, covering our older Indigo vascular thrombectomy offerings but excluding Lightning 7 and 12 for now, closed a quarter sooner than we had anticipated and added $5 million in incremental revenue during the first quarter. In China overall, despite recent lockdowns, we have solid visibility into our business and anticipate healthy growth there in 2022. We're thrilled to announce that our computer-aided mechanical aspiration technology is launching in Europe. We just obtained CE mark for Lightning 7 as well as Lightning 12, and the first cases using both products have gone very well. Our committed Vascular sales team in Europe, which we built during 2021, is fully ready to deliver this key technology to European patients dealing with arterial and venous clot, including pulmonary embolisms. Turning to coronary, in late March a new study appeared in the Journal of Interventional Cardiology confirming the remarkable data from the CHEETAH study for CAT RX, which was presented last November at the TCT conference. This study, named ROPUST, is an independent data set demonstrating that frontline use of CAT RX to aspirate coronary clot before angioplasty results in less distal embolization and improved TIMI 3 flow. Both are key predictors of favorable long-term outcomes for these patients. The investigators stated they "strongly believe that the Penumbra CAT RX device should be used before any balloon angioplasty in patients with high thrombus burden." Our efforts to reach more of these patients are advancing well and will keep going. To sum up, Vascular is our biggest business, and the number of patients we can help in our target markets is substantial and underpenetrated. We're growing worldwide thanks to our distinctive Lightning offerings, and when you put together what we already sell with what's coming down the pipeline — I'll get into that in a few minutes — we feel really good about our ability to produce robust expansion across multiple years. In Q1, our Neuro segment reached $81.1 million, up 1.3% versus the same period in 2021. Stroke sales around the world rose 3%, matching what we had anticipated. Compared with Q4, stroke revenue declined sequentially because of a change in our China revenue mix tied to our broader vascular partnership with Genesis. We anticipate that the split between Neuro and Vascular sales in China will move around from one quarter to the next while rising on the whole. Notably, our stroke operation in the U.S. posted mid-teens growth compared with a year earlier. In fact, we think we've reached a pivotal juncture in the ischemic stroke space, even though a wealth of clinical data accumulated over prior years demonstrates that mechanical thrombectomy is indisputably the optimal treatment approach for large vessel occlusions. Just 1 in 4 such patients in the U.S. receive this kind of care. The existing stroke treatment model has gotten us here, yet we owe patients better. Truly, drawing on everything we've discovered about stroke thrombectomy across the last 18 years, among them numerous years devoted to Thunderbolt, I have great optimism that we stand at the edge of a fresh chapter in treating stroke. We're eager to validate our conviction through the Thunderbolt trial. Although the IDE hasn't been granted yet, we anticipate a single-arm study enrolling roughly 150 patients, with the usual short-term endpoints. Enrollment should begin this summer. If Thunderbolt delivers the results we expect, our goal is to bring it to market in 2023. In the meantime, we'll advance the field using novel catheter technology that will act as a key bridge toward — and an essential piece of — the coming Thunderbolt paradigm. Because RED 62, 68 and 72 launched successfully across the United States in 2021, our U.S. stroke operation once again posted robust growth this quarter. I anticipate our U.S. stroke operation will notch record quarters as 2022 progresses, powered by RED and the energy surrounding our Thunderbolt trial; on top of that, we intend to broaden our RED lineup in the U.S. in the latter part of this year, which we believe may lift our U.S. stroke operation late in 2022 and afterward. Beyond the U.S., we're bringing the RED catheter lineup to Japan this quarter. Japan matters greatly to us, and we perceive enormous potential there in the years ahead — not only for our new neuro offerings but for our vascular thrombectomy offerings as well. Additionally, we intend to introduce our RED catheters across Europe in the second half of this year. For us, this marks the first time in over 3 years that new stroke products will arrive in the EMEA region, and we believe that will lead to stronger growth there. All told, no one else has a Neuro portfolio for stroke that is as strong as ours, and we anticipate that fresh RED catheter launches across the globe, together with enrollment in the Thunderbolt trial, will create momentum for this business throughout 2022; once we get to 2023 and afterward, we believe Thunderbolt's launch could speed up our business. Now let's discuss Immersive Healthcare. Our progress has been tremendous, and starting later this year we intend to share metrics that reflect that progress, centered on 3 key areas: first, developing new products across hardware, software and content; second, how many third-party partnerships we have, which ought to bring scale to the content available on our platform; and third, partnerships with major companies across a number of sizable health care channels, which will grow the installed base of our REAL System in the United States. Since the REAL System launched in the U.S. during the pandemic's early days, we have treated close to 4,000 patients. We have bolstered our visibility at major industry trade shows, such as last month's HIMSS meeting, where 40,000 people were in attendance. Talking with hundreds of prospective partners has confirmed our business model and our strategy for this emerging market.

Adam Elsesser

executive
#3

We're breaking ground with the first full-scale platform for immersive health care, and we'll keep putting suitable resources into this key area. Now I want to take a few minutes for some broad thoughts regarding our company and the things that will drive growth going forward. On the whole, we're enjoying gains from our expanding operations; we're putting money into our team and efforts to develop markets so we can serve additional patients, investing in proportion to the countless opportunities for growth in the markets and regions we target; in short, we'll keep bringing new ideas to both interventional and immersive health care, while we operate a profitable company during 2022 and afterward. We're moving swiftly toward $1 billion in worldwide revenue, a target we first established prior to the pandemic at our Investor Day in 2019, when our company was about half that size. Our expansion has happened organically, through creating products that matter to patients in 6 sizable markets; we remain quite early in each of the 5 interventional markets, and our Immersive Healthcare business, which might grow to become our biggest business within 5 to 6 years, is delivering the sort of progress I anticipated when I laid out our vision at the Investor Day last fall. On earlier calls, we've concentrated on our history and our accomplishments. We take pride in both, yet we need to say more about where we're set to head next. Our primary markets are clearly appealing, and that naturally draws rivals. Even so, we should be explicit about how we'll keep winning. Our dedication to bettering patient outcomes will fuel our leadership in these markets, and our expansion stems directly from our culture of innovation, whose central tenets are innovation that is distinctive, ongoing and effective. That culture doesn't just keep us at the forefront of patient care, it also lets us reshape paradigms, elevating patient care to a new plane. For 18 years, we've deliberately worked to safeguard removing blood clot from the body, beginning with the brain, then moving to the arterial system, the coronary vasculature and the venous system. We've pushed innovation in this area far past merely a catheter and a suction source. We understand what matters in a thrombectomy system to perform this task with the greatest safety and efficacy. To start, technology that prevents removing an excessive amount of blood from the body matters. Navigating the correctly sized catheter matched to the particular anatomy swiftly and safely matters. Getting all of the clot out matters. Intelligent, uninterrupted power aspiration matters. And last, carrying out all this work within the vasculature without inflicting trauma on the blood vessel matters. Compromises among these essential criteria in clot removal are no longer tolerable, since our innovation in 2 central areas has made them unnecessary: incorporating computer technology into the thrombectomy system and creating next-generation catheter technology. We're going to push hard into this model so that our physician clients can see the distinct advantages of employing our technology to treat patients who have clots in their veins, arteries, coronary vessels and neurovasculature. Given that, I'd like to share additional specifics regarding the fresh offerings headed your way within the interventional portion of our company. To begin, we think we have products that could reshape the paradigm arriving within the next 18 months across both neuro and vascular. Those include Thunderbolt for ischemic strokes, which we've already covered, plus major innovative updates to our Lightning lineup for DVT and PE, along with a brand-new technology called Lightning Bolt aimed at arterial clot — and both of these merge and build upon our most recent technology. Beyond that transformative technology, we intend to bring to market a number of products designed to strengthen and broaden our distinctive portfolios in Neuro as well as Vascular. Over the course of our history, pairing paradigm-shifting innovation with distinctive growing products has widened the leadership positions we hold in the markets where we concentrate. Crucially, our growing scale and expansion create the chance to bring in further leaders who will grow our ability to expand far into the future. I'm pleased to share news of 2 new senior leaders joining us: Sandra Lesenfants has come aboard Penumbra as President of our Interventional business, and Joe Sendra has joined as Senior Vice President of Operation and Strategy. Sandra's career has been spent in the interventional arena, with her last 2 interventional roles leading structural heart and endovenous, respectively, at Medtronic. Joe has built his career at Johnson & Johnson, most recently serving as Vice President, Worldwide Engineering and Technology; on top of that, we successfully moved to a new ERP system in early April. That represents a tremendous volume of effort and demanded collaboration spanning a wide cross-section of our worldwide team. This remarkable undertaking covered 2.5 years of meticulous planning and execution. It's essential given our growing size and scale. The ERP transition ranks among a handful of noteworthy investments we've made across the past 2 years to bolster our supply chain, enlarge our manufacturing capacity and strengthen our leadership team. The gross margin gain this quarter is an encouraging beginning, and we anticipate further productivity gains down the road. And each of these investments forms the foundation of our pledge to keep delivering robust, lasting growth. Last, I was traveling again during the first quarter, meeting with over 40 physicians nationwide. It was wonderful to be back face to face with both current and prospective customers. We gained plenty of insight into what they face each day and how we can assist them in treating their patients more effectively in this new environment as they keep grappling with staffing shortages. Almost all of the people we talked with anticipate the staffing shortage problem persisting for a while. And that is prompting hospitals to become far more sharply focused on pricing and cost inside their systems. We got a lot of positive feedback regarding the way we approach pricing as an organization, and also about how what we offer is enabling them to effectively care for patients dealing with a substantial clot burden. The way we think about pricing is something we've held to for a long time and it's intentional, and it has played a part in building an advantage that's sustainable and competitive, in the near term as well as over the long term. At this point I'll hand things over to Maggie so she can walk through our financial results for the quarter.

Maggie Yuen

executive
#4

Thanks, Adam. Hello, everyone, and good afternoon. On today's call, I'll go over our financial results for Q1 2022. Revenue and gross margin figures discussed here are GAAP-based, whereas operating expenses and operating loss income are presented on a non-GAAP basis. You can find the corresponding GAAP measures along with reconciliations between GAAP and non-GAAP financial measures in the press release we posted. For Q1, which ended March 31, 2022, total revenues reached $203.9 million, up 20.5% as reported and up 21.8% on a constant currency basis versus the first quarter of 2021. Sales mix by geography during the quarter came in at 70.8% U.S. and 29.2% international. U.S. and international each posted reported growth of 20.2% and 21.3%, respectively, against the same period in 2021. Turning to revenue by franchise. Our Vascular business brought in $122.8 million in Q1 2022, which represents a 37.7% reported increase and a 38.8% constant currency increase over the same period last year. Versus the prior quarter, Vascular revenue rose 8.1%, fueled by strong U.S. peripheral thrombectomy performance and our expanded China partnership, as Adam mentioned earlier. Our Neuro business generated $81.1 million in Q1 2022, up 1.3% as reported and up 2.9% in constant currency versus the same period a year ago. Against Q1 2021, we recorded double-digit growth in U.S. neuro thrombectomy, partly offset by a product mix shift from neuro to vascular in China during the quarter. Now for gross margin and operating expenses. Gross margin for Q1 came in at 62.5%, versus 65.8% in last year's same quarter, though it rose sequentially from 61.5% in the prior quarter. Although gross margin has faced some pressure over the past 12 months because of accelerated investment in capacities and direct labor supporting manufacturing transfer activities, our productivity initiatives have delivered great progress. Gross margin was up 100 basis points from last quarter even with inflation headwinds and greater Omicron-related labor absenteeism early in the quarter. As we look toward the rest of this year, we anticipate gradual margin expansion will continue, driven by labor efficiency and productivity improvements. Now to our operating expenses. During the quarter, amortization of acquired intangible assets in SG&A was $1.8 million, and in the prior quarter we recorded onetime SG&A expenses tied to the Sixense acquisition plus amortization of acquired intangible assets totaling $10 million. Accordingly, the financial metrics below reflect non-GAAP results, which exclude the impact of those expenses. Total operating expense for the quarter was $129.7 million, or 64% of revenue, versus $97.9 million, or 58% of revenue, in last year's same quarter. Our research and development expenses for Q1 2022 came to $20.6 million, compared with $18.1 million for Q1 2021. Looking at SG&A, in Q1 2022 that came to $109.1 million, which works out to 54% of revenue. That compares with $79.8 million in Q1 2021, and $103.5 million versus the prior quarter. The year-over-year rise in SG&A came from adding head count, more travel and other in-person activities, plus investment in facilities and infrastructure. On a sequential basis, the SG&A increase included $5 million tied to seasonal first quarter spending — things like our national sales meeting for both the Neuro and Vascular teams, which came back to in-person this year — along with other variable expenditures. We're still putting money into new product development and commercial resources, and with key facilities and infrastructure investment now complete to support scalability for future growth, we anticipate operating expenses will rise at a slower sequential pace in 2022. In the first quarter of 2022, we posted an operating loss of $2.3 million, or negative 1.1% of revenue, against operating income of $13.5 million in the same period a year earlier. We closed the first quarter with cash, cash equivalents and marketable securities totaling $240.3 million, and working capital levels held steady. At this point I'd like to hand the call to Jason so he can go over our guidance.

Jason Mills

executive
#5

Thanks, Maggie, and good afternoon to all of you. We are reaffirming our 2022 revenue outlook of $860 million to $875 million, which would mean 15% to 17% growth compared with 2021 revenue of $747.6 million. Following a sluggish beginning to 2022, driven partly by staffing shortages that hit hospital customers throughout our industry, our team delivered accelerating growth during the first quarter, particularly in the United States; we also gained from an expansion of our China business that came sooner than anticipated, pulling into Q1 just over $5 million that we had initially thought would arrive in the second quarter. Going forward, this quarter also brings the toughest year-over-year comparison we will face all year, thanks to the successful launches of 2 major products in the second quarter a year ago: Lightning 7 and RED 62. All told, we anticipate a modest sequential rise in our second quarter revenue, which translates to a year-over-year growth rate in the low teens in Q2. We anticipate our growth will speed up in both the third and fourth quarters, with Q4 growth expected to reach or slightly exceed the top end of our annual growth guidance range of 15% to 17%. Further out, although we are not providing formal guidance yet for 2023, we are optimistic that we could accelerate our revenue growth rate in 2023 compared to 2022 from our interventional business alone, based on what we expect from new products and geographic growth opportunities. The possibility of material contribution from Immersive Healthcare comes on top of this expectation. Lastly, we anticipate additional gross margin expansion and operating profitability gains through the remainder of 2022 and 2023, all while we keep making meaningful investments in our business to drive long-term growth. I will now hand the call back to Adam for closing remarks.

Adam Elsesser

executive
#6

Thanks, Jason, Maggie, and Jee. To wrap up what we've prepared to say today, I'd like to make one thing very clear: Penumbra exists to develop and pioneer the finest technology that assists patients across a wide range of fields. That effort is carried out with care and rigor, yet also with tremendous urgency; having reached our 18th year, Penumbra has demonstrated the ability to accomplish this and thrive under any conditions. Thanks. Operator, please begin the question-and-answer portion of the call.

Larry Biegelsen

analyst
#7

I've got a quick clarification, plus a product-related question. Adam, could you walk us through what took place in China during this quarter, and how should we interpret that $5 million figure? Was that a one-time stocking gain? And if I heard it right, why was it booked under Vascular rather than Neuro? If you could just shed a bit more light on that, I'd appreciate it. Then I have one follow-up.

Adam Elsesser

executive
#8

Of course. As you're aware, our arrangement with China — and we've mentioned this on numerous occasions — encompasses several components: distribution, licensing, and royalties. This particular piece was a new addition. Previously, the China agreement covered only a modest set of our older stroke Neuro offerings — 5 of them, to be precise. One of those, as I recall, was an access tool. This marked the initial occasion where we brought the vascular portion into the arrangement, and our expectation had been to get it done during the second quarter, yet we managed to finish it sooner and close it in the first quarter. That explains why it landed here, driven by those revenue streams arriving a quarter ahead of schedule.

Larry Biegelsen

analyst
#9

Let me just ask one more thing about that, Adam — what would have made Neuro take a hit during this quarter? Then I'll move to my second item. You mentioned there are major iterations coming for DVT and PE. What sort of detail are you able to give us right now, I suppose, is the real question? Which unmet needs are you aiming to solve? And Lightning Bolt — clearly, you'd figure I would bring that up. Any detail at all on it, and might any of these fresh product launches show up during 2022? During the prior call, you mentioned a few new vascular launches were coming this year. If I need to say any of that again, just tell me. My apologies for that.

Adam Elsesser

executive
#10

Yes. I believe — no, I believe I captured all of them. I'll begin with the final item. Yes, what we hope and expect is that you'll see those 2 vascular products you referenced, or that we discussed at the very close of 2022; that's definitely quite likely and quite possible; having said that, let me go through it as well as I can without reaching the point where, as you're aware, we face lots and lots of competitors here. And we must be somewhat mindful about revealing every product detail, even though with these products, there's some genuinely strong patent protection, and that has us pretty excited; we, as you're aware, haven't always had that. Yet even so, I believe you'd agree, and most investors would agree, that certain things must stay more confidential until the products launch. But return to what I stated earlier in the script — what are — how do you remove clot? Which things matter? And I listed very clearly the things that matter so you can remove clot safely without drawing too much blood and without harming the vessel. As we move into the next phase, we've reached a point, and we want to keep building on that, where those trade-offs are no longer necessary. And since you've tracked us for a long time, you know those trade-offs have always been made regarding how you remove clot. And we've now reached a point where we don't believe this new technology will require you to make any trade-offs. And that matters a great deal, because if we're going to reach the point where this is performed everywhere — it's a democratized procedure and you no longer have to consider other means of handling blood clot in the body — you can't be doing it with trade-offs. So those are — that's where we're headed. And the reason we set that out so clearly is we hold a lot of confidence that we're nearly there now, but we'll be there without any question very soon. And by saying we've nearly arrived at this point, what I mean is that, measured against others, what we offer already handles that job quite impressively at present. Our goal is simply to reach a stage where the experience becomes progressively more effortless, and that prospect has us genuinely enthusiastic.

Larry Biegelsen

analyst
#11

About the Lightning Bolt and that $5 million — sorry, Adam, but why exactly did the $5 million come out of neurovascular? I get why there'd be stocking for vascular, but I don't get why it came from — it sounded like neurovascular was where it came from.

Adam Elsesser

executive
#12

Let me — Jason can give you those specifics.

Jason Mills

executive
#13

Correct. Neuro wasn't harmed by it. With only the earlier byproduct arrangement in place, we had anticipated strong expansion in China. What happened was that Vascular got folded into that combination a quarter sooner than expected. Consequently, taking everything together, our business in China will — as Adam pointed out, it draws on several different revenue streams, and Larry, it's going to swing from quarter to quarter between Neuro and Vascular. On the whole, we're looking for strong expansion from China both this year and in the years ahead. Yet Neuro did not lose anything because of it; it contributed to the broader Chinese business, which came in at $5 million above what we had expected for the first quarter. Clearly it remains below 10 — comfortably below 10% of total revenue, otherwise we would have reported it separately.

Robbie Marcus

analyst
#14

Nice work on the quarter. Could I ask about the guidance? Maggie, perhaps you could explain the thinking behind the beat. Even removing that $5 million from China, the quarter still beat by $4 million, yet guidance was reaffirmed. So please explain the puts and takes, and why you chose to keep guidance as is?

Jason Mills

executive
#15

Sure. Robbie, I'll try to answer first, and then others may want to add something, if that works. Excellent question. Looking at the first half of the year, compared with where consensus stood and where people were positioned coming into the quarter, I believe we're running ahead of that. The first quarter exceeded our expectations and, clearly, beat consensus by a wide margin, partly due to a stronger overall quarter and partly due to that $5 million we had thought would arrive in the second quarter. But the key point is that the first half is perhaps performing slightly better than what we had assumed when we initially provided that guidance. Then the second part, regarding your question about reaffirming guidance rather than taking a different action, at this early stage in the year we simply wanted to account for the moving pieces, both on the macro side and because we want more clarity on the timing of our own product launches that we discussed on this call, along with the product launches we discussed internationally and their pace. So at this point in the year, we considered it wise to keep that guidance, which we were clearly very pleased with when we issued it a quarter ago.

Robbie Marcus

analyst
#16

All right, then let's just attribute that to caution at the start of the year, and there's nothing more to infer from it.

Jason Mills

executive
#17

That's my view.

Robbie Marcus

analyst
#18

Okay. Perhaps if I shift over to the Neuro segment, the growth rates have been affected. There's no way for us to tell what portion of that $5 million shifted between the two, so for part a, I'm curious whether you might provide adjusted growth rates that leave out the China contract. And for part b, this is a market where growth rates have decelerated and there are plenty of competitors. Other folks are mentioning that competition in neuro has picked up. So perhaps you might offer us a brief state of the union — what you're observing regarding underlying growth, geographic growth, whether it differs. And whatever effects competitors are having.

Adam Elsesser

executive
#19

Sure. So when you examine the international business, especially in this quarter, it clearly becomes somewhat tougher to go country by country and make comparisons. What I believe you need to focus on is that if you examine our U.S. stroke business, we continued to expand at a mid-teens pace, which was quite solid on a year-over-year basis, and we felt quite good about that. Having said that, there's no doubt — and I believe I was quite blunt during my prepared remarks — when discussing the condition of the stroke market. We've accomplished something remarkable, not just our company, but the other industry partners along with the physicians, especially across the last 7 years, expanding this market from when the first — the stroke trials were initially announced. It's remarkable. And we've reached roughly 25% of those patients receiving treatment. And my remarks regarding this, the next wave or the next era, I believe we need to breathe new life into this field. We must have the sort of paradigm shift that carried us this far, and I believe Thunderbolt is drawing that attention. As we've begun enrolling people for the trial and showing the product, it's evident from their response that this is something different, and that it will deliver the sort of impact we're hoping for on patient care, and likely supply the energy that's required to do the truly, truly difficult work to keep this market expanding. So I think that's the state of the universe there or of the field, so to speak; it is a competitive market. There's a huge number of companies with catheters of every kind of shape and size right now. But that isn't going to be what drives it. That isn't how the story ends. And that's the reason we're especially excited about it, the reason we've laid out the size and timing of the trial. So clearly, to the best of our ability, given that the IDE hasn't been issued. And I think you can tell we're leaning in quite heavily because we believe this is going to help not only treat patients better, but drive growth on top of the growth rate that we've witnessed over the past bunch of years.

Jason Mills

executive
#20

Right. Robbie, Jason here. You raised something regarding the Vascular segment, leaving China aside; in the remarks we had ready, we noted we figured that would come up, that within the United States our vascular thrombectomy business expanded by more than 30%. So with luck, that serves to offer you some feel for how strong our Vascular business is beyond — or if you take out that portion from China.

Robbie Marcus

analyst
#21

Since we aren't given a geographic split by segment, can you provide the worldwide figures?

Jason Mills

executive
#22

Sorry — worldwide figures for which item?

Robbie Marcus

analyst
#23

If we leave that out, what about the change in revenue mix?

Jason Mills

executive
#24

Sure, that's actually pretty straightforward to calculate. All you'd need to do is take that $5 million out of what our Vascular business brought in. Our Vascular business posted substantial growth — it came in above 40%. So the result wouldn't end up very different from that figure.

Brandon Vazquez

analyst
#25

Brandon here, filling in for Margaret. My main area of interest was the vascular segment. You folks have put up some truly remarkable expansion over the past few years. And typically in med devices, once you get deeper into the adoption curve, growth might start arriving from other segments, other channels, perhaps other functions, or new accounts versus ones you already have — that kind of thing. So I was wondering whether you could spend a moment on where the growth is originating right now, where it will originate in 2022, and compare that with what happened in the earlier phases of the adoption curve; and also, what white space remains for you, since you're still fairly early in penetrating the broad market. Adam, over to you.

Adam Elsesser

executive
#26

Yes, terrific question, Brandon. During my prepared remarks, I stated plainly that we keep observing — and I'd characterize it as sequential expansion — throughout all 4, with the U.S. as the focus, since that's where Lightning is sold, all 4 of those markets. That means DVT, PE, coronary and arterial. Across all 4, growth persisted. And that's what we anticipate. Clearly it won't be uniform from quarter to quarter, given that our field team concentrates on specific accounts, the caseloads those accounts carry, and the particular specialty of the physicians involved, yet every one of those is expanding, and there's genuine traction with the products. Ultimately it circles back to something I said during the prepared remarks: when people use these products, when they discuss them with one another, they come to understand that, truly for the first time, no trade-offs are required. They're employing properly sized catheters featuring smart technology — Lightning — which addresses blood loss as well as your position within the vasculature relative to the clot. And they're achieving excellent results with it. It's demonstrating that it's the sort of product they can picture using routinely. That's the path to growth for us. So we're quite optimistic that where we stand now with these products will carry forward. In this response I neglected to bring up CAT RX on the coronary side; but clearly we're witnessing that too, continuing to perform well following the CHEETAH study and then the ROPUST study that came after; so every one of them looks quite healthy. And I believe moving forward, we'll witness expansion across all of them.

Brandon Vazquez

analyst
#27

All right; and turning to markets outside the U.S., you folks have Lightning beginning to launch over there, possibly the highest-impact product introduction your company has ever done. I believe that was pretty straightforward to observe in the U.S. at the time it came out, and plainly in the numbers we're looking at, it has unquestionably ranked among the strongest products we've encountered. So perhaps you could share a bit about how large the sales team you currently have abroad is? What sort of chance are you bringing this into during this year? How many nations do you intend to enter? And what further investments do you expect to make overseas as you get ready for that launch?

Adam Elsesser

executive
#28

Yes. So the launch in Europe is at the very, very beginning. Naturally, we issued a release about it stating we were handling the initial cases; those have gone extremely well. I didn't travel to Charing Cross, but Sandra Lesenfants, our new President of Interventional, did, and this is an area she understands very well, met with several key opinion leaders who attended the Charing Cross meeting in London; and I can tell you, the appetite, the enthusiasm for this product is truly strong. What this product, both Lightning 7 and Lightning 12, accomplish in their particular domains was grasped. The sole distinction in Europe, and this is simply a fact, not a warning and not intended as a warning, is that it's somewhat more of a patchwork quilt of reimbursement from one country to the next. And we're on top of that, and we'll navigate that. So that's somewhat different from the U.S., clearly. But I'm genuinely, genuinely thrilled about it. Regarding the size of our sales team, we've already been selling our peripheral coil over there, so we had established a fairly robust sales force. So I don't believe we need to expand it for some time. And it's really just doing the work like we've done in the U.S. to get the product out there and get it used and see the growth. So once more, excited about the future with it too.

Joanne Wuensch

analyst
#29

I have 2 questions. The SG&A line came in above what I had modeled. Can you break that down for me, so I can determine which portion is, I suppose, recurring, though it might only recur through the rest of the year? And which portion is more one-time in nature and drove that figure higher?

Maggie Yuen

executive
#30

All right. Yes. I appreciate the question, Joanne; when you compare total SG&A spending with a year ago, there are likely 3 main drivers behind the increase. The first is simply that a great deal of in-person events and marketing conferences have returned. I believe a year ago, we actually noted that this gave us a 10% decrease in our total SG&A expense. The second driver concerns investment in headcount spanning our functions. And the third driver concerns certain facilities and infrastructure spending; so looking ahead, as we discussed in Q1, there is some seasonality around things like sales meeting and one-time costs, more seasonal in character, roughly $5 million; and moving forward, the increases will likely taper progressively each quarter.

Adam Elsesser

executive
#31

Right. Let me just jump in on that. For anyone who's been tracking us over an extended period, we've been fairly tight when it comes to what we spend, and the level of control we hold here is significant. The money going out serves a purpose. We've been very direct that — especially at this moment, as we move into what is, in a sense, a somewhat different set of conditions, something we're plainly well aware of — we won't let ourselves get over our skis; we understand how to avoid that. And that's really the argument we were attempting to put forward regarding that portion of the ledger.

Joanne Wuensch

analyst
#32

My next question relates to a product, and it concerns REAL. You sound as though you're moving forward with it, and the phrasing suggests there's more coming in the next year. However, I'm somewhat, a, wondering whether I heard that right; and b, is it possible to at last say a bit about how the ramp could shape up? Could they become somewhat more concrete rather than less REAL?

Adam Elsesser

executive
#33

Yes, we can. Our aim in being very clear was to set out the initial round of information and metrics that we will deliver later this year. That, I believe, is the launching point for beginning to discuss further specifics, the business models along with timing and the ramp. That, I think, will be the proper launching point. If not, it turns into something more theoretical. And up to now, clearly, the majority of people have held off to witness REAL's tangible success; and therefore those metrics I mentioned will serve as the launching point for that success. And I'd like to, sort of, make one additional point. When Penumbra was founded many, many years back, 18 years back, there was — the notion of treating stroke patients was truly far-fetched. People — the physicians didn't truly all wish to do the thing. There was no reimbursement, there was nothing patentable. Every sort of obstacle; yet we have established a culture surrounding this company in which we understand how to enter areas nobody has gone and carve out that work. We've accomplished it on the peripheral side too, and we're presently accomplishing it in an immersive health care platform; and so you — it has never been accomplished before. And so you will need to grant us a bit of leeway to perform the work required. What I will say to you, and it's genuinely encouraging to witness, is we've had numerous conversations with every side of this, both on the developer side, but perhaps most crucially on the user side. And there is considerable interest. There is considerable knowledge. There's considerable understanding regarding the benefit that immersive computing has on many, many people's health care. So — and there's considerable interest that we got the model right. There's considerable acknowledgment that they require one source of platform, but they desire all of the content that they can have. So we feel genuinely, genuinely good about where we're sitting at this moment. And the next time we truly go into the details, you'll begin to hear some of that success.

Jason Mills

executive
#34

And Joanne, I’ll just give a bit more context around what Adam said. To return to something I mentioned earlier in my prepared comments: Immersive Healthcare could potentially deliver a meaningful contribution, and that would come on top of the 20 — that is, the expectation for 2023 of faster growth. So if you end up somewhere within our guidance range for this year, our view is that we can speed up next year based only on our interventional business. Still, we made sure to note that Immersive Healthcare may contribute. As Adam said, we’d like to reach a stage with those 3 points where we can discuss it in greater detail as we move toward the later part of the year.

David Rescott

analyst
#35

Nice work on the quarter. Let me start with the Vascular segment. My sense is that during the last 2 years, or maybe even before that, when you looked at the neurothrombectomy side of things, you consistently noted that a number of new players had entered this area — I'm not certain whether that's 10 or 15 — mainly beyond the bigger competitors who showed up and occasionally grabbed some share here, yet honestly never made a significant dent, as I understand it, in your market share. And once more, that's setting aside the bigger companies. Given some of the approvals that have happened lately in vascular, what's your view on how the product and the portfolio stand apart? And then, set against what you went through in the neurovascular segment, how are you thinking about your competitive standing from here on out?

Adam Elsesser

executive
#36

Yes. Look, that's a completely reasonable question; and everyone tracking us is aware that I won't turn to this call, or anything else, to get into specifics about any individual company or rival. That wouldn't be right. What is right, however, is doing what we've already done today — stating in the clearest possible terms what it takes to lead when it comes to extracting clot. If you slap something together fast, just to get it finished and shipped, this field won't regress. It will keep progressing. The standards I laid out truly matter for treating patients and for the way this area evolves. We recognize that, and so do physicians; and it won't be like the old days where I could simply devise a catheter plus an aspiration source — or a device that scrapes along the vessel wall. As we enter the next, more advanced stage, those tools no longer qualify. So, all things considered, we feel quite comfortable and sure about the effort we've invested across 18 years to get this right; and I believe we're positioned well to keep demonstrating that we can build the finest products for pulling clot out.

David Rescott

analyst
#37

All right, that's useful. My follow-up is about Thunderbolt, I suppose. So you've likely got some perspective by now regarding the aim of genuinely making stroke care accessible to everyone, delivering this — or at minimum widening the adoption of such a treatment across more stroke centers. So what I'm wondering is: if the data truly confirms it, and Thunderbolt grows into a technology of that kind, one that genuinely paves the way for thrombectomy to be used more widely in the U.S.? How ought we to view this technology being extended to a broader set of designated stroke centers? What I'm asking is whether expanding the therapy would require something like a change in guidelines? Or perhaps there's some easy win, or a route, maybe toward a primary care center or primary stroke care centers, or possibly even acute stroke rated hospitals that might lack those particular stroke designations, yet as we all know, already perform procedures of this kind.

Adam Elsesser

executive
#38

Yeah. That's a genuinely good question, and in my view it has several dimensions. Given that hospitals have been grappling with their own staffing challenges, there's been greater reliance on locums and similar arrangements; so plenty of effort is underway, yet I believe everything boils down to this: if the clot can be removed more quickly, more simply, and more effectively, then naturally that should rekindle the enthusiasm in this specialty, which the last 2 years of COVID have made extremely difficult. So I'd say it's a relatively straightforward thing to recognize when we consider what's required to get doctors involved again, get hospitals involved again, and have them understand this is something they enjoy doing and wish to do. That's where I believe Thunderbolt comes in. And for our part, to repeat for everyone, in contrast to catheter technology, which truly couldn't be patented, we hold issued patents covering this technology. And that, I'd say, places us somewhere different from where we've stood before. So once more, quite an exciting period. But listen, we're nearing the point when we'll begin treating patients. Let's hold off and observe how that unfolds. I'm hopeful about it, but let's observe how that unfolds, and we'll follow up once we've treated our first few patients.

Jason Mills

executive
#39

Right, and David, Jason here. I want to build on that point. You raised something about vascular, and something about neuro — essentially regarding procedures and the competitive landscape. Near the close of his second response, Adam brought up technology and innovation, noting that computer-aided innovation can be patented. It's worth reminding everyone that this same situation applies to the computer technology we're applying on the vascular side. So that technology isn't just something we're able to protect — it also lets us remove the trade-offs that other technologies may face when they attempt to optimize the core criteria of clot removal. That's a critical component now present for us on both the vascular and neuro sides, and it is unique to Penumbra.

Ryan Zimmerman

analyst
#40

I'll try to fit in 3 questions, hopefully they're brief, but I'm going to make them very quick. First, regarding China, I'd like to build on what Larry asked before. Value-based purchasing is expanding with recon devices, and next it will cover spine; and the final piece that we're at least aware of at this point is neuro. I just want to check, are you anticipating any effect? Since I don't believe it's been specified yet what falls under the neuro segment; so is there any consequence we should factor in from a value-based purchasing program or its effect in China? And then the remaining 2 questions, I'll pose them right away. As you launch into Japan with RED and bring it into Europe with certain products, what effect on margins do you expect that to have in those markets compared to the rest of the business? And given all this focus, and this is only the third question, given all this focus on margin that we've heard and the people you've brought on, Adam, might we anticipate some long-term margin goals to go along with the $1 billion target you've established.

Adam Elsesser

executive
#41

Those are excellent questions, Ryan. We'll attempt to address them — let me go in reverse order. And then Jason and Maggie can chime in here. I value the request for a margin target. I don't have that answer since we haven't discussed it within the company; and the notion that I'd promise that while sitting here with Maggie staring at me, I simply won't do that. But it's a reasonable request, and we'll consider it. I'll say this, our aim has always been to achieve the highest suitable margin we can. We don't want to — we — once more, we discussed our pricing approach so that we set prices for long-term sustainability. So that involves a suitable margin, but we can certainly return over time to where we stood historically prior to COVID; so that's it. Japan and Lightning and Thunderbolt and so forth, and RED, as we transition into the computer-aided technology, those carry somewhat improved margins. And so I believe we'll be okay, moving forward. And then the last question concerned China. I'm going to have Jason address that.

Jason Mills

executive
#42

Absolutely, Ryan. Regarding China, we’re definitely monitoring and staying current with the economic details you brought up there, like value-based pricing and so on. And what I’d say is that throughout our collaborative efforts with Genesis—and as you’re aware, this stretches back several years now—the two of us have talked about that. We’ve taken it into account during our conversations as we built the framework that’s powering our revenue through those various channels we’ve talked about in China alongside our partner, Genesis. So yes, we’re keeping an eye on it, but we were deliberate—we chose our language carefully in the script, where Adam, I believe, noted that we have very strong visibility into our China business; we also mentioned that we anticipate, I think the words were solid growth in China. We expect our overall Chinese business to expand. So ideally, those 2 points, plus the remarks about us staying on top of macroeconomic matters, address that question; and just to revisit one of your earlier questions that Adam handled, broadly speaking, in neurothrombectomy, our thrombectomy products in particular tend to have higher margins worldwide, meaning both in the United States and globally. So I think that gives you a bit of extra insight on that aspect.

Mike Matson

analyst
#43

I know we're pressed for time, so I'll limit myself to a single question. Regarding your U.S. Vascular sales team — my understanding is that it's one unified force, though please correct me if that's wrong. At what stage might you consider splitting it up and having representatives specialize in particular subsegments? In other words, do you think you're disadvantaged relative to some of the smaller, more narrowly focused competitors — ones that, say, work only on the venous side?

Adam Elsesser

executive
#44

No, I don't think so. You know there are 3 subspecialties among the physicians, and in the end every one of them handles the 4 areas: coronary, arterial, DVT and PE. The rotation isn't constant. Sometimes every one of those pieces clicks together, other times it doesn't. So my sense is that the path we've chosen allows us to reach a wide range of areas. As a reminder, should we ever find ourselves at a — personally I don't view it as a drawback; in fact I'd call it a benefit — but the team stays occupied since, on top of the thrombectomy side, we also have the coil side, meaning they're spread across many areas; alongside our sales force, we have clinical specialists who bring enormous value and form an absolutely essential piece of our organization, collaborating directly with sales reps across different territories. So my feeling is that we're positioned quite well. I need to be straight with you—and pardon me for a moment—but I want to give credit where it's due to the finest group of people ever assembled in our Vascular business. The effort they've put in, their commitment, and the honesty they bring to how they sell—it fills me with pride. It's honestly remarkable. So all things considered, we're sitting in a solid position.

Pito Chickering

analyst
#45

Alright, two fast product-related questions. Could you share some detail about how coronary volumes looked during the quarter following CHEETAH — specifically regarding how many new centers and new physicians have adopted it, and what the reorder trends look like for them? Then, turning to neuro, do you have any insight into our current U.S. market share with RED compared to what it was before the recall? Also, how did growth rates compare at the close of the quarter versus its start, when you were up against the January COVID comparisons?

Adam Elsesser

executive
#46

Sure. I'll take the final question first, then we can move backward from there. As with everybody else, clearly March came in far stronger than January, which you'd expect in any quarter. I believe most would share that view, though it was even more pronounced this time around because January — particularly the early portion — stood out due to so many people being out and staffing challenges. So we feel we're on a solid path as the quarter progressed, and we were quite happy with how we closed things out, clearly. Regarding splitting out each individual item, we haven't taken that approach. That's not something we've done; perhaps at some stage we will in the future, but I doubt it. When we consider the business and actually discuss it with our sales reps, we're handling all of this simultaneously, and that matters a great deal. We don't set up separate categories and objectives for each element. Our aim is to keep reaching every patient who could benefit from our products. And it truly undermines how we operate the business and communicate with our customers to discuss things in those sorts of specific terms. So for now, we won't be doing that, but I really appreciate the question.

Jason Mills

executive
#47

Sure, Pito — I'll just give a bit more context on that other question. Regarding share of the market, here are a few broad points. Our position in U.S. drug thrombectomy has clearly gotten much better following the JET 7 XTRA FLEX recall in early last year. The larger idea we want to get across has 2 parts. First, as we kick off the Thunderbolt trial and progress through it — and we shared particular information not just on that trial, but on when we anticipate approval, and clearly what we believe will occur following that approval for our Neuro business — we discussed expectations for ongoing gains during this year as other RED products get launched. And I suppose the second thing I want to say is this — something Adam mentioned before — which is that the stroke area, the figure counted within others, has carried the stroke area to where it is now. Yet we only treat 1 out of 4 patients who need help, who might benefit from these systems. And I believe the momentum surrounding this area will gain considerably from technology that simply performs better. And it's enabling this procedure to be performed more widely, and Thunderbolt represents that model. So that's what we're driving toward. Meanwhile, we believe we'll perform well with our business, with the RED catheters. And then — I think you also inquired about coronary. Coronary was robust during the quarter. We saw solid growth across all 4 segments of our vascular thrombectomy business. We won't report it as a separate line, but it was robust.

Jee Hamlyn-Harris

executive
#48

Thanks, operator. Our management team and I want to say once more how much we appreciate everyone being here today and the attention you're giving Penumbra. We're eager to bring you up to date during this call about our second quarter.

Operator

operator
#49

Thank you. This concludes today's conference call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.